Navidea Biopharmaceuticals, Inc (NYSE:NAVB) persists its position slightly strong in context of buying side, while shares price ascend 5.70% during latest trading session.
Navidea Biopharmaceuticals, Inc. (NYSE:NAVB) revealed that it has executed a Letter of Intent with Cardinal Health, Inc. (CAH) for the sale of all rights, title and interest to Navidea’s Lymphoseek product for all FDA-approved, pending and future oncology diagnostic indications in North America, subject to certain limitations, as well as certain other related assets. Under the terms of the LOI, Navidea would receive $80 million at closing, with future consideration tied to annual sales of the Lymphoseek product and certain sales-based milestones. Total consideration to Navidea would be capped at $310 million.
Narrow down focus to other ratios, the co has current ratio of 0.10 that indicates if NAVB lies in 1.3% to 3% then it is acceptable for both active and passive investors, but sometimes its varies industry to industry. Generally, it indicates good short-term financial strength. Street is more conscious on this after SunEdison, Inc. case. To make strengthen these views, the active industry firm has Quick Ratio of 0.10, which indicates firm has sufficient short-term assets to cover its immediate liabilities.
Following previous ticker characteristics, Amicus Therapeutics, Inc. (NASDAQ:FOLD) also run on active notice, stock price raised 0.43% after traded at $7.05 in most recent trading session.
FOLD has price to earnings ratio stands at unstated figure and the price to current year EPS stands at -29.80%. Whereas the traders who further want to see about this, may be interested to see Price to next year’s EPS that would be 25.90%. Moving toward ratio analysis, it has current ratio of 2.70 and quick ratio was calculated as 2.70. The debt to equity ratio appeared as 0.00 for seeing its liquidity position.
Taking notice on volatility measures, price volatility of stock was 4.54% for a week and 5.72% for a month. The price volatility’s Average True Range for 14 days was 0.38. On these bases, analysts would recommend this stock as an “Active Revolving Stocks.” The firm attains analyst recommendation of 1.90 out of 1-5 scale with week’s performance of 1.15%. FOLD’s institutional ownership was registered as 97.60%, while insider ownership was 0.60%.